trial
shows
efficacy
filgotinib
induction
maintenance
remission
moderately
severely
active
ulcerative
colitis
brussels
stock
exchange
glpg
filgotinib
achieved
endoscopic
histologic
remission
week
consistent
safety
profile
study
enrolled
patients
high
proportion
highly
refractory
foster
city
mechelen
belgium
october
cet
gilead
sciences
nasdaq
gild
galapagos
nv
euronext
nasdaq
glpg
today
presented
data
demonstrating
sustained
efficacy
safety
filgotinib
investigational
oral
preferential
inhibitor
treatment
moderately
severely
active
ulcerative
colitis
uc
data
randomized
phase
selection
trial
showed
significantly
higher
proportion
patients
treated
filgotinib
mg
versus
placebo
achieved
clinical
remission
week
maintained
remission
week
addition
significantly
patients
achieved
remission
full
results
presented
today
united
european
gastroenterology
week
uegw
virtual
meeting
abstracts
uc
condition
characterized
inflammation
mucosal
lining
colon
rectum
increasingly
prevalent
disease
uc
significant
impact
quality
life
million
people
around
world
despite
current
treatments
many
patients
experience
fecal
urgency
incontinence
recurring
bloody
diarrhea
need
empty
bowels
frequently
often
accompanied
abdominal
pain
poor
sleep
fatigue
remains
tremendous
need
treatments
achieve
meaningful
sustained
clinical
outcomes
ulcerative
colitis
said
laurent
md
phd
gastroenterology
department
lorraine
university
france
presenting
investigator
selection
maintenance
study
study
results
showed
filgotinib
reduced
bleeding
stool
frequency
also
achieving
remission
across
range
measures
including
endoscopy
histology
oral
selection
study
included
patients
prior
conventional
therapy
failed
well
patients
high
proportion
least
two
different
lines
prior
biologics
total
percent
patients
cohort
failed
treatment
tnf
inhibitor
vedolizumab
study
allowed
enrollment
patients
taking
steroids
immunomodulators
including
methotrexate
mercaptopurine
azathioprine
would
clinical
practice
efficacy
data
filgotinib
induction
maintenance
overall
adult
patients
moderately
severely
active
uc
randomized
treated
selection
study
among
patients
treated
filgotinib
mg
significantly
higher
proportion
patients
achieved
clinical
remission
week
compared
placebo
additionally
significantly
higher
proportion
patients
treated
filgotinib
mg
versus
placebo
achieved
mayo
clinic
score
mcs
remission
endoscopic
remission
histologic
remission
p
significantly
higher
proportion
patients
treated
filgotinib
achieved
clinical
remission
week
compared
placebo
patients
treated
filgotinib
achieved
clinical
response
remission
week
induction
dose
filgotinib
placebo
ratio
treated
week
maintenance
trial
week
percent
patients
receiving
filgotinib
mg
achieved
clinical
remission
compared
percent
patients
treated
placebo
significantly
higher
proportion
treated
filgotinib
mg
versus
placebo
achieved
sustained
clinical
remission
mcs
remission
p
endoscopic
remission
histologic
remission
p
additionally
significantly
higher
proportion
patients
treated
filgotinib
mg
achieved
clinical
remission
week
compared
placebo
safety
outcomes
filgotinib
ulcerative
colitis
overall
incidence
adverse
events
aes
serious
aes
discontinuations
due
aes
similar
filgotinib
placebo
groups
induction
maintenance
periods
study
serious
infections
herpes
zoster
venous
thrombosis
pulmonary
embolism
gastrointestinal
perforation
infrequent
comparable
across
treatment
groups
common
adverse
events
interest
induction
trials
serious
infections
filgotinib
mg
filgotinib
mg
placebo
herpes
zoster
filgotinib
mg
filgotinib
mg
placebo
opportunistic
infections
filgotinib
mg
filgotinib
mg
placebo
pulmonary
embolism
filgotinib
mg
filgotinib
mg
placebo
maintenance
trial
common
adverse
events
interest
serious
infections
filgotinib
mg
filgotinib
mg
placebo
herpes
zoster
filgotinib
mg
filgotinib
mg
placebo
venous
thrombosis
filgotinib
mg
filgotinib
mg
placebo
two
deaths
observed
filgotinib
mg
treatment
group
maintenance
trial
adverse
events
leading
deaths
considered
study
investigators
unrelated
study
drug
ulcerative
colitis
complex
unpredictable
condition
impact
people
prime
lives
despite
treatment
people
uc
experience
symptoms
significant
impact
quality
life
said
mark
genovese
md
senior
vice
president
inflammation
gilead
sciences
pleased
share
data
use
filgotinib
uc
work
identify
new
treatment
options
address
unmet
needs
across
range
inflammatory
selection
study
assessed
efficacy
safety
filgotinib
patients
ulcerative
colitis
including
high
proportion
patients
refractory
biologic
treatment
need
new
treatment
options
said
walid
chief
medical
officer
galapagos
efficacy
safety
data
seen
filgotinib
patient
population
add
growing
body
evidence
demonstrating
potential
treatment
may
offer
patients
living
debilitating
selection
phase
trial
selection
phase
trial
randomized
trial
assess
safety
efficacy
preferential
inhibitor
filgotinib
adult
patients
moderately
severely
active
uc
selection
trial
comprises
two
induction
trials
maintenance
trial
induction
study
enrolled
patients
induction
study
b
enrolled
patients
across
induction
studies
patients
moderately
severely
active
uc
randomized
receive
filgotinib
mg
filgotinib
mg
placebo
ratio
moderately
severely
active
uc
defined
centrally
read
endoscopy
score
rectal
bleeding
score
stool
frequency
score
physician
global
assessment
pga
based
mcs
patients
clinical
remission
response
week
induction
subsequently
induction
dose
filgotinib
placebo
ratio
treated
week
primary
objectives
selection
evaluate
efficacy
filgotinib
compared
placebo
establishing
clinical
remission
determined
mayo
endoscopic
subscore
rectal
bleeding
subscore
decrease
stool
frequency
baseline
achieve
subscore
week
induction
studies
week
maintenance
study
eligible
patients
enrolled
selection
trial
enrolled
ongoing
selection
extension
trial
evaluate
safety
filgotinib
patients
moderately
severely
active
uc
filgotinib
filgotinib
mg
mg
tablets
approved
europe
japan
treatment
adults
moderately
severely
active
rheumatoid
arthritis
ra
responded
inadequately
intolerant
one
disease
modifying
drugs
dmards
full
european
summary
product
characteristics
filgotinib
available
european
medicines
agency
ema
website
interview
form
japanese
ministry
health
labour
welfare
mhlw
available
filgotinib
approved
anywhere
treatment
ulcerative
colitis
filgotinib
collaboration
gilead
galapagos
nv
collaborative
partners
global
development
filgotinib
rheumatoid
arthritis
inflammatory
bowel
disease
inflammatory
indications
companies
conducting
global
studies
investigating
potential
role
filgotinib
variety
diseases
including
phase
selection
trial
uc
actively
enrolling
phase
trial
crohn
disease
diversity
information
clinical
trials
filgotinib
accessed
gilead
sciences
gilead
sciences
biopharmaceutical
company
discovers
develops
commercializes
innovative
medicines
areas
unmet
medical
need
company
strives
transform
simplify
care
people
illnesses
around
world
gilead
operations
countries
worldwide
headquarters
foster
city
california
information
gilead
sciences
please
visit
company
website
galapagos
galapagos
nv
discovers
develops
small
molecule
medicines
novel
modes
action
three
show
promising
patient
results
currently
development
multiple
diseases
pipeline
comprises
discovery
phase
programs
inflammation
fibrosis
osteoarthritis
indications
ambition
become
leading
global
biopharmaceutical
company
focused
discovery
development
commercialization
innovative
medicines
information
gilead
statement
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
subject
risks
uncertainties
factors
also
possibility
unfavorable
results
ongoing
additional
clinical
trials
involving
filgotinib
including
selection
extension
trial
diversity
trial
possible
parties
may
make
strategic
decision
discontinue
development
ﬁlgotinib
treatment
ulcerative
colitis
indications
result
filgotinib
may
never
successfully
commercialized
treatment
ulcerative
colitis
indications
statements
statements
historical
fact
statements
could
deemed
statements
risks
uncertainties
factors
could
cause
actual
results
diﬀer
materially
referred
statements
reader
cautioned
rely
statements
risks
described
detail
gilead
form
quarter
ended
june
filed
securities
exchange
commission
statements
based
information
currently
available
gilead
gilead
assumes
obligation
update
statements
galapagos
statement
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
amended
subject
risks
uncertainties
factors
could
cause
actual
results
diﬀer
materially
referred
statements
therefore
reader
place
undue
reliance
risks
uncertainties
factors
include
without
limitation
risk
ongoing
future
clinical
studies
filgotinib
may
completed
currently
envisaged
timelines
inherent
uncertainties
associated
competitive
developments
clinical
trial
product
development
activities
regulatory
approval
requirements
including
data
ongoing
planned
clinical
research
programs
may
support
registration
development
filgotinib
ulcerative
colitis
indications
due
safety
efficacy
reasons
galapagos
reliance
collaborations
third
parties
including
collaboration
partner
filgotinib
gilead
galapagos
estimations
regarding
filgotinib
development
program
regarding
commercial
potential
filgotinib
may
incorrect
well
risks
uncertainties
identified
annual
report
form
year
ended
december
subsequent
filings
sec
statements
statements
historical
fact
statements
could
deemed
statements
statements
contained
herein
based
management
current
expectations
beliefs
speak
date
hereof
galapagos
makes
commitment
update
publicly
release
revisions
statements
order
reflect
new
information
subsequent
events
circumstances
changes
expectations
contacts
galapagos
investors
media
elizabeth
goodwin
carmen
vroonen
vp
ir
global
head
communications
public
affairs
sofie
van
gijsel
anna
gibbins
senior
director
ir
senior
communications
director
therapeutic
areas
ir
communications
contacts
gilead
investors
media
douglas
maffei
phd
marian
cutler
attachment
